Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: health care management considerations.

    ... approved for this indication-- azacitidine and decitabine --in terms of proven effectiveness, safe delivery, and survival ... discussion and study. The therapies azacitidine and decitabine may offer a good model for decision making to drive best treatment ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. How we treat higher-risk myelodysplastic syndromes

    ... the hypomethylating agents azacitidine and decitabine , which should be administered for a minimum of 6 cycles, and ...

    Research Article last updated 01/08/2014 - 8:57am.

  3. Myelodysplastic syndromes: What do hospitalists need to know?

    ... therapy. The addition of azacitidine , decitabine , and lenalidomide to erythropoiesis-stimulating agents ...

    Research Article last updated 06/20/2013 - 10:59am.

  4. Prognostic role of immunohistochemical analysis of 5mc in Myelodysplastic Syndromes.

    ... effectiveness; the drugs azacitidine and decitabine have been approved for the treatment of MDS. METHOD: We ...

    Research Article last updated 06/20/2013 - 10:57am.

  5. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

    ... hypomethylating agents (HMAs) azacitidine and decitabine have changed the treatment landscape of myelodysplastic ...

    Research Article last updated 01/03/2013 - 9:48am.

  6. Myelodysplastic syndromes: therapy and outlook

    ... such as lenalidomide , azacitidine , and decitabine are available for those who previously would have received ...

    Research Article last updated 07/31/2012 - 1:27pm.

  7. Combination strategies in myelodysplastic syndromes.

    ... lenalidomide , azacitidine , and decitabine are the only three FDA-approved drugs for MDS. Traditional ...

    Research Article last updated 04/24/2012 - 2:18pm.

  8. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

    ... inhibitors, 5-azacytidine and 5-aza-2'-deoxycytidine or decitabine , represent frontline nonablative treatments, while combinations ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... for treatment of MDS: (1) azacitidine , (2) decitabine , and (3) lenalidomide . Clinical results with each of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... include hypomethylating agents ( azacitidine and decitabine ), intensive chemotherapy (ICT), and allogeneic stem-cell ...

    Research Article last updated 10/11/2011 - 5:58pm.